second-line

You have access
Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab
KUNIHIDE MOHRI, HIDENARI NAGAI, TAKAHISA MATSUDA, YOSHINORI IGARASHI and KOJI HIGAI

Anticancer Research September 2024, 44 (9) 3919-3929; DOI: https://doi.org/10.21873/anticanres.17220
You have access
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow
ALESSANDRO RIZZO, ANGELA DALIA RICCI, NASTASSJA TOBER, MARIA CONCETTA NIGRO, MIRTA MOSCA, ANDREA PALLONI, FRANCESCA ABBATI, GIORGIO FREGA, STEFANIA DE LORENZO, SIMONA TAVOLARI and GIOVANNI BRANDI

Anticancer Research June 2020, 40 (6) 3013-3030; DOI: https://doi.org/10.21873/anticanres.14282
You have access
Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors
JACOPO GIULIANI and ANDREA BONETTI

Anticancer Research July 2019, 39 (7) 3961-3965; DOI: https://doi.org/10.21873/anticanres.13550
You have access
Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer
WENJING WONG, PING SUN, ZHENGBIN MU, JIANNAN LIU, CAIYAN YU and AINA LIU

Anticancer Research August 2017, 37 (8) 4687-4691;
You have access
Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma
HIDEAKI MIYAKE, SATOSHI IMAI, KEITA TAMURA, TAKAYUKI SUGIYAMA, HIROSHI FURUSE, SEIICHIRO OZONO and MASATO FUJISAWA

Anticancer Research March 2017, 37 (3) 1523-1528;
You have access
Second-line Treatment of Advanced Gastric Cancer: Current Options and Future Perspectives
PAWEL CHROM, RAFAL STEC and CEZARY SZCZYLIK

Anticancer Research September 2015, 35 (9) 4575-4583;
You have access
No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma
AKIRA MIYAZAKI, HIDEAKI MIYAKE, KEN-ICHI HARADA and MASATO FUJISAWA

Anticancer Research May 2015, 35 (5) 3067-3073;
You have access
Sequential Treatment of Advanced-stage Lung Adenocarcinoma Harboring Wild-type EGFR Gene: Second-line Pemetrexed Followed by Third-line Erlotinib versus the Reverse Sequence
ONDREJ FIALA, MILOS PESEK, JINDRICH FINEK, LUCIE BENESOVA, ZBYNEK BORTLICEK and MAREK MINARIK

Anticancer Research August 2013, 33 (8) 3397-3402;

Main menu

User menu

Search

second-line